Skip to main content
TipRanks
Go Ultimate75% OFF

Crispr Therapeutics AG (CRSP) Operating Expense Breakdown

11,100 Followers

Operating Expense Breakdown

Crispr Therapeutics AG reported operating expenses of $124.98M in Q2 2026, down 5.1% from Q1 2026 and down 6.7% year over year. The highest value was $183.42M in Q2 2022.

Details core costs like R&D, marketing, and admin, offering insight into how efficiently the company runs and where it’s prioritizing investment.

$0.00$50.00M$100.00M$150.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

CRSP is moving spend away from steady internal R&D toward increasingly large, lumpy collaboration payments; R&D has eased from its 2022 peak while collaboration outlays have become the main driver of operating volatility, with G&A staying controlled. That pattern implies the company is leaning on partners and milestone-driven programs to advance assets—which can speed development and de‑risk costs but raises cash‑flow unpredictability and a potential long‑term risk if in‑house discovery is deprioritized.

CRSP Operating Expense Breakdown

PeriodResearch and DevelopmentGeneral and AdministrativeCollaborationTotal
Q2 2026Jun 30, 2026$67.15M$17.55M$40.27M$124.98M
Q1 2026Mar 31, 2026$68.57M$17.18M$45.95M$131.71M
Q4 2025Dec 31, 2025$83.53M$18.40M$53.70M$155.63M
Q3 2025Sep 30, 2025$58.90M$16.93M$57.12M$132.95M
Q2 2025Jun 30, 2025$69.89M$18.92M$45.15M$133.96M
Q1 2025Mar 31, 2025$72.48M$19.30M$57.51M$149.29M
Q4 2024Dec 31, 2024$82.16M$18.12M$10.42M$110.70M
Q3 2024Sep 30, 2024$82.16M$17.42M$11.15M$110.73M
Q2 2024Jun 30, 2024$80.17M$19.48M$52.13M$151.78M
Q1 2024Mar 31, 2024$76.17M$17.95M$46.97M$141.09M
Q4 2023Dec 31, 2023$95.14M$16.48M$20.00M$131.62M
Q3 2023Sep 30, 2023$90.70M$18.29M$23.42M$132.41M
Q2 2023Jun 30, 2023$101.56M$19.03M$44.64M$165.22M
Q1 2023Mar 31, 2023$99.94M$22.36M$42.19M$164.49M
Q4 2022Dec 31, 2022$103.56M$21.17M$6.82M$131.55M
Q3 2022Sep 30, 2022$116.62M$27.00M$38.86M$182.48M
Q2 2022Jun 30, 2022$123.22M$26.27M$33.92M$183.42M
Q1 2022Mar 31, 2022$118.25M$28.02M$30.65M$176.91M
Q4 2021Dec 31, 2021$103.09M$23.68M$31.82M$158.60M
Q3 2021Sep 30, 2021$83.50M$23.71M$22.46M$129.67M
Q2 2021Jun 30, 2021$82.33M$28.81M$26.95M$138.08M
Q1 2021Mar 31, 2021$70.62M$24.52M$19.95M$115.08M
Q4 2020Dec 31, 2020$82.36M$25.77M$0.00$108.13M
Q3 2020Sep 30, 2020$71.01M$21.54M$0.00$92.55M
Q2 2020Jun 30, 2020$59.38M$21.35M$0.00$80.73M
Q1 2020Mar 31, 2020$54.19M$19.55M$0.00$73.74M
Q4 2019Dec 31, 2019$48.76M$17.27M$0.00$66.03M
Q3 2019Sep 30, 2019$57.25M$15.52M$0.00$72.77M
Q2 2019Jun 30, 2019$39.53M$15.77M$0.00$55.30M
Q1 2019Mar 31, 2019$33.82M$14.93M$0.00$48.75M
Q4 2018Dec 31, 2018$28.80M$16.54M$0.00$45.34M
Q3 2018Sep 30, 2018$39.80M$10.20M$0.00$50.00M

Related KPIs